vs
Side-by-side financial comparison of ACTELIS NETWORKS INC (ASNS) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
ACTELIS NETWORKS INC is the larger business by last-quarter revenue ($1.4M vs $829.5K, roughly 1.6× China SXT Pharmaceuticals, Inc.). China SXT Pharmaceuticals, Inc. runs the higher net margin — -96.8% vs -184.5%, a 87.7% gap on every dollar of revenue. On growth, ACTELIS NETWORKS INC posted the faster year-over-year revenue change (28.6% vs 0.0%).
Actelis Networks Inc develops and manufactures high-performance broadband access networking solutions for telecom operators, enterprises and government entities. Its core products include Ethernet over copper systems delivering cost-effective high-speed connectivity over existing copper infrastructure, with key markets across North America, Europe and the Asia-Pacific.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
ASNS vs SXTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4M | $829.5K |
| Net Profit | $-2.5M | $-802.6K |
| Gross Margin | 35.1% | 16.2% |
| Operating Margin | -122.3% | -76.9% |
| Net Margin | -184.5% | -96.8% |
| Revenue YoY | 28.6% | 0.0% |
| Net Profit YoY | -40.1% | 0.0% |
| EPS (diluted) | $-5.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4M | — | ||
| Q3 25 | $643.0K | $829.5K | ||
| Q2 25 | $941.0K | — | ||
| Q1 25 | $721.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $2.5M | $829.5K | ||
| Q2 24 | $3.4M | — | ||
| Q1 24 | $726.0K | — |
| Q4 25 | $-2.5M | — | ||
| Q3 25 | $-2.0M | $-802.6K | ||
| Q2 25 | $-1.9M | — | ||
| Q1 25 | $-1.9M | — | ||
| Q4 24 | $-1.8M | — | ||
| Q3 24 | $-511.0K | $-802.6K | ||
| Q2 24 | $-78.0K | — | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | 35.1% | — | ||
| Q3 25 | 28.5% | 16.2% | ||
| Q2 25 | 32.4% | — | ||
| Q1 25 | 34.8% | — | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 68.6% | 16.2% | ||
| Q2 24 | 56.6% | — | ||
| Q1 24 | 30.3% | — |
| Q4 25 | -122.3% | — | ||
| Q3 25 | -300.0% | -76.9% | ||
| Q2 25 | -188.4% | — | ||
| Q1 25 | -251.3% | — | ||
| Q4 24 | -154.0% | — | ||
| Q3 24 | -12.5% | -76.9% | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | -257.7% | — |
| Q4 25 | -184.5% | — | ||
| Q3 25 | -307.9% | -96.8% | ||
| Q2 25 | -202.0% | — | ||
| Q1 25 | -258.0% | — | ||
| Q4 24 | -169.4% | — | ||
| Q3 24 | -20.1% | -96.8% | ||
| Q2 24 | -2.3% | — | ||
| Q1 24 | -273.6% | — |
| Q4 25 | $-5.08 | — | ||
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $-0.21 | — | ||
| Q1 25 | $-0.22 | — | ||
| Q4 24 | $-7.90 | — | ||
| Q3 24 | $-0.09 | $-0.25 | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $18.1M |
| Total DebtLower is stronger | — | $105.0K |
| Stockholders' EquityBook value | $4.8M | $15.4M |
| Total Assets | $9.5M | $21.7M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | — | ||
| Q3 25 | $1.5M | $18.1M | ||
| Q2 25 | $393.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $2.0M | — | ||
| Q3 24 | $2.2M | $18.5M | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | $150.0K | $105.0K | ||
| Q2 25 | $150.0K | — | ||
| Q1 25 | $150.0K | — | ||
| Q4 24 | $150.0K | — | ||
| Q3 24 | — | $952.3K | ||
| Q2 24 | — | — | ||
| Q1 24 | $148.0K | — |
| Q4 25 | $4.8M | — | ||
| Q3 25 | $3.0M | $15.4M | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | $2.6M | — | ||
| Q4 24 | $3.0M | — | ||
| Q3 24 | $3.1M | $15.0M | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $-1.7M | — |
| Q4 25 | $9.5M | — | ||
| Q3 25 | $6.9M | $21.7M | ||
| Q2 25 | $6.0M | — | ||
| Q1 25 | $7.1M | — | ||
| Q4 24 | $8.2M | — | ||
| Q3 24 | $8.8M | $31.0M | ||
| Q2 24 | $8.4M | — | ||
| Q1 24 | $10.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.05× | 0.01× | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.06× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.1M | $-1.4M |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -216.2% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.1M | — | ||
| Q3 25 | $-2.4M | $-1.4M | ||
| Q2 25 | $-1.0M | — | ||
| Q1 25 | $-2.2M | — | ||
| Q4 24 | $-1.8M | — | ||
| Q3 24 | $-2.4M | $-1.4M | ||
| Q2 24 | $-2.1M | — | ||
| Q1 24 | $-203.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-204.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -216.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -28.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASNS
| Europe Middle East And Africa | $1.1M | 83% |
| Other | $228.0K | 17% |
SXTC
Segment breakdown not available.
